Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06503016
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-05
Brief Title:
The Effect of phoSPHocreatine on mEdical Emergency Team Met tREated Patients
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Effect of phoSPHocreatine on mEdical Emergency Team Met tREated Patients a Randomized Clinical Trial Protocol
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SPHERE
Brief Summary:
Unexpected deaths and unplanned intensive care unit ICU admissions are common during hospital stay and are often preceded by warning abnormalities in patients vital signs These abnormalities trigger Medical Emergency Team MET activation and up to 15 of patients visited by the MET is admitted to the ICU with an overall hospital stay after the MET intervention of approximately 2 weeks Phosphocreatine PCr is a natural energy-buffering molecule associated with signals of mortality reduction in patients with acute cardiac conditions according to meta-analytic finding from our group and with encouraging beneficial effects on other acute organ failures eg brain The investigators designed a multi-center randomized placebo-controlled trial to confirm the promising beneficial effects of PCr in hospitalized patients The investigators expects a reduction in hospital stay measured as an increase in days alive and out of hospital at 30 days when PCr is added to standard treatment in patients requiring MET intervention
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None